Literature DB >> 10952689

Inhibition of HERG potassium channels by the antimalarial agent halofantrine.

H Tie1, B D Walker, C B Singleton, S M Valenzuela, J A Bursill, K R Wyse, S N Breit, T J Campbell.   

Abstract

Halofantrine is a widely used antimalarial agent which has been associated with prolongation of the 'QT interval' of the electrocardiogram (ECG), torsades de pointes and sudden death. Whilst QT prolongation is consistent with halofantrine-induced increases in cardiac ventricular action potential duration, the cellular mechanism for these observations has not been previously reported. The delayed rectifier potassium channel, I(Kr), is a primary site of action of drugs causing QT prolongation and is encoded by the human-ether-a-go-go-related gene (HERG). We examined the effects of halofantrine on HERG potassium channels stably expressed in Chinese hamster ovary (CHO-K1) cells. Halofantrine blocked HERG tail currents elicited on repolarization to -60 mV from +30 mV with an IC(50) of 196.9 nM. The therapeutic plasma concentration range for halofantrine is 1.67-2.98 microM. Channel inhibition by halofantrine exhibited time-, voltage- and use-dependence. Halofantrine did not alter the time course of channel activation or deactivation, but inactivation was accelerated and there was a 20 mV hyperpolarizing shift in the mid-activation potential of steady-state inactivation. Block was enhanced by pulses that render channels inactivated, and channel blockade increased with increasing duration of depolarizing pulses. We conclude that HERG channel inhibition by halofantrine is the likely underlying cellular mechanism for QT prolongation. Our data suggest preferential binding of halofantrine to the open and inactivated channel states.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952689      PMCID: PMC1572249          DOI: 10.1038/sj.bjp.0703470

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  46 in total

1.  Molecular determinants of dofetilide block of HERG K+ channels.

Authors:  E Ficker; W Jarolimek; J Kiehn; A Baumann; A M Brown
Journal:  Circ Res       Date:  1998-02-23       Impact factor: 17.367

2.  JPCalc, a software package for calculating liquid junction potential corrections in patch-clamp, intracellular, epithelial and bilayer measurements and for correcting junction potential measurements.

Authors:  P H Barry
Journal:  J Neurosci Methods       Date:  1994-01       Impact factor: 2.390

Review 3.  Drugs, QT interval abnormalities and ventricular arrhythmias.

Authors:  S H Thomas
Journal:  Adverse Drug React Toxicol Rev       Date:  1994

4.  The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum.

Authors:  B Cenni; J Meyer; R Brandt; B Betschart
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

5.  Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria.

Authors:  J Karbwang; K A Milton; K Na Bangchang; S A Ward; G Edwards; D Bunnag
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

6.  Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states.

Authors:  B D Walker; C B Singleton; J A Bursill; K R Wyse; S M Valenzuela; M R Qiu; S N Breit; T J Campbell
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

7.  The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG.

Authors:  D Rampe; M K Murawsky; J Grau; E W Lewis
Journal:  J Pharmacol Exp Ther       Date:  1998-08       Impact factor: 4.030

8.  HERG, a human inward rectifier in the voltage-gated potassium channel family.

Authors:  M C Trudeau; J W Warmke; B Ganetzky; G A Robertson
Journal:  Science       Date:  1995-07-07       Impact factor: 47.728

9.  Terfenadine blocks time-dependent Ca2+, Na+, and K+ channels in guinea pig ventricular myocytes.

Authors:  Z Ming; C Nordin
Journal:  J Cardiovasc Pharmacol       Date:  1995-11       Impact factor: 3.105

10.  Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine.

Authors:  J R Veenendaal; A D Parkinson; N Kere; K H Rieckmann; M D Edstein
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

View more
  10 in total

1.  Antiarrhythmic drug research.

Authors:  M J A Walker
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

2.  Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.

Authors:  T Kredo; K Mauff; J S Van der Walt; L Wiesner; G Maartens; K Cohen; P Smith; K I Barnes
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

Review 3.  Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling.

Authors:  M Malik; A J Camm
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Specific residues of the cytoplasmic domains of cardiac inward rectifier potassium channels are effective antifibrillatory targets.

Authors:  Sami F Noujaim; Jeanne A Stuckey; Daniela Ponce-Balbuena; Tania Ferrer-Villada; Angelica López-Izquierdo; Sandeep Pandit; Conrado J Calvo; Krzysztof R Grzeda; Omer Berenfeld; José A Sánchez Chapula; José Jalife
Journal:  FASEB J       Date:  2010-06-28       Impact factor: 5.191

5.  Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes.

Authors:  Andrew J Batey; Susan J Coker
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

6.  Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.

Authors:  José A Sánchez-Chapula; Ricardo A Navarro-Polanco; Michael C Sanguinetti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-11-19       Impact factor: 3.000

7.  Effect of experimental hyperlipidaemia on the electrocardiographic effects of repeated doses of halofantrine in rats.

Authors:  Jigar P Patel; Dion R Brocks
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

8.  Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Jun Lu; Heming Wei; Jianjun Wu; Mohd Fadzly Amar Jamil; Mei Lan Tan; Mohd Ilham Adenan; Philip Wong; Winston Shim
Journal:  PLoS One       Date:  2014-12-23       Impact factor: 3.240

9.  Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m-hydroxymexiletine.

Authors:  Roberta Gualdani; Francesco Tadini-Buoninsegni; Mariagrazia Roselli; Ivana Defrenza; Marialessandra Contino; Nicola Antonio Colabufo; Giovanni Lentini
Journal:  Pharmacol Res Perspect       Date:  2015-07-31

10.  The macrolide drug erythromycin does not protect the hERG channel from inhibition by thioridazine and terfenadine.

Authors:  Aziza El Harchi; Andrew S Butler; Yihong Zhang; Christopher E Dempsey; Jules C Hancox
Journal:  Physiol Rep       Date:  2020-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.